Skip to main content

Table 2 Dose cohort and escalation increment

From: A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer

Dose level (cohort)

Daily dose of PHI-101 (once daily)

Escalation increment from the previous dose

-1

20 mg

1 tab.

- 20 mg

- 50%

1 (starting dose)

40 mg

2 tab.

-

-

2

80 mg

4 tab.

40 mg

100%

3

120 mg

6 tab.

40 mg

50%

4

160 mg

8 tab.

40 mg

33%

5

200 mg

10 tab.

40 mg

25%

6 (maximum planned dose)

240 mg

12 tab.

40 mg

20%